Download Files:
Products Details
Product Description
– Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation[1][2].
Web ID
– HY-132849
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C30H37N7O2
References
– [1]Theravance’s nezulcitinib fails to meet Phase II goals in Covid-19|[2]Theravance biopharma, inc. Announces top-line results from phase 2 study of nezulcitinib in patients hospitalized with acute lung injury due to COVID-19
CAS Number
– 2412496-23-0
Molecular Weight
– 527.66
SMILES
– O=C(N1CC(C1)N(C)C)[C@@H]2CC3=C(CN2C(C)C)N=C(C4=NNC5=CC(C6=C(C=C(C=C6)O)CC)=CC=C45)N3
Clinical Information
– Phase 1
Research Area
– Infection; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– JAK
Isoform
– JAK
Pathway
– Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
